Anika Therapeutics (ANIK) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.20 --0%
EPS Growth %: +115.4%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +115.4%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.46, $0.01 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $27.2 million versus the consensus estimate of $28.92 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
- UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
